Effectiveness of QR678 and QR678 Neo
QR678
alopecia areata
hair regrowth therapy
intralesional corticosteroid
Journal
Journal of cosmetic dermatology
ISSN: 1473-2165
Titre abrégé: J Cosmet Dermatol
Pays: England
ID NLM: 101130964
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
revised:
22
09
2021
received:
08
03
2021
accepted:
03
11
2021
pubmed:
27
11
2021
medline:
29
12
2021
entrez:
26
11
2021
Statut:
ppublish
Résumé
Alopecia areata (AA) is an inflammatory disorder, marked by chronic, persistent, and patchy loss of hair. At present intralesional/topical corticosteroids, Minoxidil solution, and topical immune-therapies are used for treatment. Though all these have side effects and high rate of relapse. As QR678 Neo A total of 20 participants in age group of 20-50 years with nonscarring patchy hair loss were chosen for the study. Patients were arbitrarily divided into two groups (Group A-intralesional steroid with placebo and Group B-intralesional steroid with QR678 Neo Marked improvement was seen in the global assessment score after 6 months (mean- 6.6 SALT) as compared to baseline (38.5 SALT score) in group B. There was significant reduction of black dots, yellow dots, broken hairs, and tapered hair at 6 months on video dermoscopic examination in group B. Also, higher satisfaction was experienced with the treatment in group B patients. QR678 Neo
Sections du résumé
BACKGROUND
BACKGROUND
Alopecia areata (AA) is an inflammatory disorder, marked by chronic, persistent, and patchy loss of hair. At present intralesional/topical corticosteroids, Minoxidil solution, and topical immune-therapies are used for treatment. Though all these have side effects and high rate of relapse. As QR678 Neo
MATERIALS AND METHODS
METHODS
A total of 20 participants in age group of 20-50 years with nonscarring patchy hair loss were chosen for the study. Patients were arbitrarily divided into two groups (Group A-intralesional steroid with placebo and Group B-intralesional steroid with QR678 Neo
RESULT
RESULTS
Marked improvement was seen in the global assessment score after 6 months (mean- 6.6 SALT) as compared to baseline (38.5 SALT score) in group B. There was significant reduction of black dots, yellow dots, broken hairs, and tapered hair at 6 months on video dermoscopic examination in group B. Also, higher satisfaction was experienced with the treatment in group B patients.
CONCLUSION
CONCLUSIONS
QR678 Neo
Substances chimiques
Adrenal Cortex Hormones
0
Minoxidil
5965120SH1
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
358-367Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Cash TF. The psychology of hair loss and its implications for patient care. Clin Dermatol. 2001;19(2):161-166.
Masmoudi J, Sellami R, Ouali U, et al. Quality of life in alopecia areata: a sample of tunisian patients. Dermatol Res Pract. 2013;2013:983804. doi:10.1155/2013/983804
Dabek RJ, Roh DS, Ozdemir D, et al. Fractional laser-assisted hair regrowth and microneedling for the treatment of alopecia areata: a review. Cureus. 2019;11(6):e4943. doi:10.7759/cureus.4943
Rantuccio F, Mastrolonardo M, Conte A. Area Celsi. Osservazioni personali e revisione della letteratura. G Ital Dermatol Venereol. 1995;130:23-35.
Dawber R. Alopecia areata. Monogr Dermatol. 1989;2:89-102.
Roest YBM, van Middendorp HT, Evers AWM, van de Kerkhof PCM, Pasch MC. Nail involvement in alopecia areata: a questionnaire-based survey on clinical signs, impact on quality of life and review of the literature. Acta Derm Venereol. 2018;98:212-217.
Mendieta-Eckert M, Landa-Gundin N, Torrontegui-Bilbao J. Treatment of patchy and universalis alopecia areata with fractional laser. Dermatol Surg. 2019;46(3):430-433.
Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J. Alopecia areata update: part I. Clinical picture, histopathology, and pathogenesis. J Am Acad Dermatol. 2010;62(2):177-188. quiz 89-90.
Mushtaq S, Raihan MD, Lone A, Mushtaq M. Alopecia areata - a literature review. Int Arch BioMed Clin Res. 2017;3(1):7-10. doi:10.21276/iabcr.2017.3.1.2
Mirzoyev SA, Schrum AG, Davis MD, Torgerson RR. Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester epidemiology project, 1990-2009. J Invest Dermatol. 2014;134(4):1141-1142.
Hull SPM, Wood ML, Hutchinson PE, Sladden M, Messenger AG. Guidelines for the management of alopecia areata. Br J Dermatol. 2003;149:692-699. doi:10.1046/j.1365-2133.2003.05535.x
Guzmán-Sánchez DA, Villanueva-Quintero GD, Alfaro Alfaro N, McMichael A. A clinical study of alopecia areata in Mexico. Int J Dermatol. 2007;46(12):1308-1310.
Yang S, Yang J, Liu JB, et al. The genetic epidemiology of alopecia areata in China. Br J Dermatol. 2004;151(1):16-23.
Olsen E, Hordinsky M, McDonald-Hull S, et al. Alopecia areata investigational assessment guidelines. National alopecia areata foundation. J Am Acad Dermatol. 1999;40:242-246.
Delamare FM, Sladden MJ, Dobbins HM, Leonardi-Bee J. Interventions for alopecia areata. Cochrane Database Syst Rev. 2008;2:CD004413.
Arca E, Kurumlu Z. Etiopathogenesis, clinical features, and diagnosis in alopecia areata. Dermatose. 2003;2:83-89.
Tak WJ, Chung YS, Ro BI. A clinical study on alopecia areata (1996-2000) (TGF-VI). Korean J Dermatol. 2002;40(7):791-800. Korean.
Rivitti EA. Alopecia areata: a revision and update. An Bras Dermatol. 2005;80(1):57-68.
Liu LY, King BA, Craiglow BG. Health-related quality of life (HRQoL) among patients with alopecia areata (AA): a systematic review. J Am Acad Dermatol. 2016;75(4):806-812.e3.
Firooz A, Firoozabadi MR, Ghazisaidi B, Dowlati Y. Concepts of patients with alopecia areata about their disease. BMC Dermatol. 2005;5:1.
Papadopoulos L, Bor R. Psychological Approaches to Dermatology. BPS Books/in lived experience of AA; 1999.
Kapoor R, Shome D, Vadera S. QR 678 hair growth factors formulation - in vivo cellular toxicity & in vivo animal efficacy study. Plast Reconstr Surg Glob Open. 2020;8:e2843.
Kapoor R, Shome D. Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth - safety and efficacy evaluation in a first-in-man pilot clinical study. J Cosmet Laser Ther. 2018;20:369-379.
Kapoor R, Shome D, Vadera S, Ram MS. QR678 & QR678 Neo Vs PRP- a randomized, comparative, prospective study. J CosmetDermatol. 2020;19(11):2877-2885. doi:10.1111/jocd.13398
Kapoor R, Shome D, Doshi K, Patel G, Vadera S. Evaluation of efficacy of QR 678 and QR678 neo hair growth factor formulation for the treatment of female pattern alopecia in patients with PCOS-a prospective study. J Cosmet Dermatol. 2020;19(10):2637-2646.
Kapoor R, Shome D, Doshi K, Vadera S, Patel G, Kumar V. Evaluation of efficacy of QR678® and QR678 Neo® hair growth factor formulation for the treatment of persistent chemotherapy-induced alopecia caused due to cytotoxic chemotherapy- a prospective pilot study. J Cosmet Dermatol. 2020;19(12):3270-3279.
Olsen EA, Hordinsky MK, Price VH, et al. Alopecia areata investigational assessment guidelines-part II. J Am Acad Dermatol. 2004;51(3):440-447.
Williamson D, Gonzalez M, Finlay AY. The effect of hair loss in quality of life. J Eur Acad Dermatol Venereol. 2001;15(2):137-139.
Cartwright T, Endean N, Porter A. Illness perceptions, coping and quality of life in patients with alopecia. Br J Dermatol. 2009;160(5):1034-1039.
Sellami R, Masmoudi J, Ouali U, et al. The relationship between alopecia areata and alexithymia, anxiety and depression: a case-control study. Indian J Dermatol. 2014;59(4):421.
Chu SY, Chen YJ, Tseng WC, et al. Psychiatric comorbidities in patients with alopecia areata in Taiwan: a case-control study. Br J Dermatol. 2012;166(3):525-531.
Kakourou T, Karachristou K, Chrousos G. A case series of alopecia areata in children: impact of personal and family history of stress and autoimmunity. J Eur Acad Dermatol Venereol. 2007;21(3):356-359.
Shi Q, Duvic M, Osei JS, et al. Health-Related Quality of Life (HRQoL) in alopecia areata patients - a secondary analysis of the National alopecia areata registry data. J Investig Dermatol Symp Proc. 2013;16(1):S49-S50.
Tosti A. Practice gaps. Alopecia areata and comorbid conditions. JAMA Dermatol. 2013;149(7):794.
Lai VWY, Chen G, Gin D, Sinclair R. Systemic treatments for alopecia areata: a systematic review. Australas J Dermatol. 2019;60:e1-e13.
Messenger AG, McKillop J, Farrant P, McDonagh AJ, Sladden M. British association of dermatologists’ guidelines for the management of alopecia. Br J Dermatol. 2012;166:916-926. doi:10.1111/j.1365-2133.2012.10955.x
Charuwichitratana S, Wattanakrai P, Tanrattanakorn S. Randomized double-blind placebo-controlled trial in the treatment of alopecia areata with 0.25% desoximetasone cream. Arch Dermatol. 2000;136:1276-1277.
Kubeyinje EP. Intralesional triamcinolone acetonide in alopecia areata amongst 62 Saudi Arabs. East Afr Med J. 1994;71:674-675.
Pratt CH, King LE Jr, Messenger AG, Christiano AM, Sundberg JP. Alopecia Areata. Nat Rev Dis Primers. 2017;3:17011.
Kurosawa M, Nakagawa S, Mizuashi M, et al. A comparison of the efficacy, relapse rate and side effects among three modalities of systemic corticosteroid therapy for alopecia areata. Dermatology. 2006;212:361-365.
Singh A, Yadav S. Microneedling: advances and widening horizons. Indian Dermatol Online J. 2016;7:244-254.
Ito T, Yoshimasu T, Furukawa F, Nakamura M, Tokura Y. Three-microneedle device as an effective option for intralesional corticosteroid administration for the treatment of alopecia areata. J Dermatol. 2017;44:e304-e305.
Deepak SH, Shwetha S. Scalp roller therapy in resistant alopecia areata. J Cutan Aesthet Surg. 2014;7:61-62.
Shome D, Kapoor R, Vadera S, Doshi K, Patel G, Mohammad KT. Evaluation of efficacy of intradermal injection therapy vs derma roller application for administration of QR678 Neo® hair regrowth formulation for the treatment of androgenetic alopecia-a prospective study. J Cosmet Dermatol. 2021;20(10):3299-3307
Buhl AE. Minoxidil's action in hair follicles. J Invest Dermatol. 1991;96(Suppl):73S-74S.
Fenton DA, Wilkinson JD. Topical minoxidil in the treatment of alopecia areata. Br Med J. 1983;287:1015-1017. doi:10.1136/bmj.287.6398.1015
Kranseler JS, Sidbury R. Alopecia areata: update on management. Indian J Paediatr Dermatol. 2017;18:261-266.
Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther. 2019;13:2777-2786.
Shome D, Kapoor R, Doshi K, Patel G, Vadera S, Kumar G. Comparison of QR 678® & QR678® Neo as monotherapy and as combination therapy with 5% Minoxidil solution and oral Finasteride in the treatment of male androgenetic alopecia-which is better? J Cosmet Dermatol. 2021;20(6):1-3.
Yalici-Armagan B, Elcin G. The effect of neodymium: yttrium aluminum garnet and fractional carbon dioxide lasers on alopecia areata: a prospective controlled clinical trial. Dermatol Surg. 2016;42:500-506. doi:10.1097/DSS.0000000000000649
Issa MCA, Pires M, Silveira P, Xavier De Brito E, Sasajima C. Transepidermal drug delivery: a new treatment option for areata alopecia? J Cosmet Laser Ther. 2015;17:37-40. doi:10.3109/14764172.2014.967778
Mlacker S, Aldahan AS, Simmons BJ, et al. A review on laser and light-based therapies for alopecia areata. J Cosmet Laser Ther. 2017;19:93-99.
Jun M, Lee NR, Lee WS. Efficacy and safety of superficial cryotherapy for alopecia areata: a retrospective, comprehensive review of 353 cases over 22 years. J Dermatol. 2017;44:386-393.
Ayatollahi A, Hosseini H, Gholami J, Mirminachi B, Firooz F, Firooz A. Platelet rich plasma for treatment of nonscarring hair loss: systematic review of literature. J Dermatolog Treat. 2017;28(7):574-581. doi:10.1080/09546634.2017.1303571
Lee S, Zheng ZH, Kang J, et al. Therapeutic efficacy of autologous platelet-rich plasma and polydeoxyribonucleotide on female pattern hair loss. Wound Rep Reg. 2015;23:30-36.
Ovidio R, Roberto M. Limited Effectiveness of platelet-rich-plasma treatment on chronic severe alopecia areata. Hair Ther Transplant. 2014;4(1):116.
Mubki T. Platelet-rich plasma combined with intralesional triamcinolone acetonide for the treatment of alopecia areata: a case report. J Dermatol Dermatol Surg. 2016;20(1):87-90.
Darwin E, Hirt PA, Fertig R, Doliner B, Delcanto G, Jimenez JJ. Alopecia areata: review of epidemiology, clinical features, pathogenesis, and new treatment options. Int J Trichol. 2018;10:51-60.
ClinicA, AsperA, MittalA, et al. Evaluation of safety and efficacy of intradermal administration of QR678 Neo® hair growth factor formulation- a multi-ethnicity clinical trial. J Cosmet Dermatol. (Submitted).
Shome D, Kapoor R, Doshi K, Patel G, Vadera S, Khan T. Evaluation of effectiveness of QR678® & QR678 Neo® hair growth factor formulation in post-hair transplant patients. J Cosmet Dermatol. (Submitted).
Circolo A, Pierce GF, Katz Y, Strunk RC. Antiinflammatory effects of polypeptide growth factor. J Biol Chem. 1990;265(9):5066-5071.